Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Selling, General & Admin	37.02	16.12	10.7	10.73	9.13	7.12	5.33	4.85	5.03	1.24	Upgrade
Research & Development	63.81	54.23	44.98	31.93	23.56	19.04	13.74	9	6.97	22.22	Upgrade
Operating Expenses	100.83	70.36	55.68	42.66	32.69	26.16	19.07	13.85	12	23.47	Upgrade
Operating Income	-100.83	-70.36	-55.68	-42.66	-32.69	-26.16	-19.07	-13.85	-12	-23.47	Upgrade
Interest Expense / Income	0	0	0	0	0	0	0	0.02	0.09	0.07	Upgrade
Other Expense / Income	-14.93	-1.49	-0.69	-3.17	-6.91	-4.1	1.51	0.86	11.32	-1.65	Upgrade
Pretax Income	-85.9	-68.87	-54.99	-39.5	-25.78	-22.06	-20.58	-14.73	-23.4	-21.88	Upgrade
Net Income	-85.9	-68.87	-54.99	-39.5	-25.78	-22.06	-20.58	-14.73	-23.4	-21.88	Upgrade
Shares Outstanding (Basic)	94	77	77	73	72	58	26	16	6	4	Upgrade
Shares Outstanding (Diluted)	94	77	77	73	72	58	26	16	6	4	Upgrade
Shares Change	22.79%	-0.47%	6.34%	0.89%	24.97%	121.65%	59.59%	156.11%	51.79%	104.93%	Upgrade
EPS (Basic)	-0.91	-0.90	-0.71	-0.54	-0.36	-0.38	-0.79	-0.90	-3.68	-5.23	Upgrade
EPS (Diluted)	-0.91	-0.90	-0.71	-0.54	-0.36	-0.38	-0.79	-0.90	-3.68	-5.23	Upgrade
Free Cash Flow	-73.38	-48.4	-47.59	-21.78	-24.75	-18.76	-14.76	-11.07	-8.73	-1.59	Upgrade
Free Cash Flow Per Share	-0.78	-0.63	-0.62	-0.30	-0.34	-0.33	-0.57	-0.68	-1.37	-0.38	Upgrade
EBITDA	-85.6	-68.58	-54.69	-39.22	-25.52	-22.06	-20.58	-14.71	-23.32	-21.81	Upgrade
Depreciation & Amortization	0.29	0.29	0.3	0.28	0.26	0	0	0	0	0	Upgrade
EBIT	-85.9	-68.87	-54.99	-39.5	-25.78	-22.06	-20.58	-14.71	-23.32	-21.81	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).